WO2011093818A3 - Pharmaceutical compositions comprising salmeterol and fluticasone - Google Patents
Pharmaceutical compositions comprising salmeterol and fluticasone Download PDFInfo
- Publication number
- WO2011093818A3 WO2011093818A3 PCT/TR2011/000020 TR2011000020W WO2011093818A3 WO 2011093818 A3 WO2011093818 A3 WO 2011093818A3 TR 2011000020 W TR2011000020 W TR 2011000020W WO 2011093818 A3 WO2011093818 A3 WO 2011093818A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical compositions
- salmeterol
- fluticasone
- pharmaceutically acceptable
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical compositions in dry powder form comprising salmeterol xinafoat and fluticasone propionate and/or their pharmaceutically acceptable derivatives as active agents, and capsule forms containing these pharmaceutical compositions so as to be used in treatment of respiratory tract diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2010/00685A TR201000685A2 (en) | 2010-01-29 | 2010-01-29 | Pharmaceutical preparations containing salmeterol and fluticasone. |
TR2010/00685 | 2010-01-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011093818A2 WO2011093818A2 (en) | 2011-08-04 |
WO2011093818A3 true WO2011093818A3 (en) | 2012-02-23 |
Family
ID=44141818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2011/000020 WO2011093818A2 (en) | 2010-01-29 | 2011-01-28 | Pharmaceutical compositions comprising salmeterol and fluticasone |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR201000685A2 (en) |
WO (1) | WO2011093818A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2494730C1 (en) * | 2012-03-27 | 2013-10-10 | Шолекс Девелопмент Гмбх | Inhalation preparation for treating respiratory diseases containing micronised salmeterol xinafoate and micronised fluticasone propionate as active substances and method for preparing it |
US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
CN104350063B (en) | 2012-05-08 | 2018-01-05 | 尼科斯眼药公司 | Preparation, its preparation method and the application of hydrophobic therapeutic agent |
US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
WO2014202513A1 (en) * | 2013-06-17 | 2014-12-24 | Arven Ilac Sanayi Ve Ticaret A.S. | Inhalation composition filling method |
WO2022045994A1 (en) * | 2020-08-28 | 2022-03-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028535A2 (en) * | 1999-10-21 | 2001-04-26 | Glaxo Group Limited | Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate |
WO2002069979A2 (en) * | 2001-03-07 | 2002-09-12 | Glaxo Group Limited | Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
WO2003033000A1 (en) * | 2001-10-12 | 2003-04-24 | Glaxo Group Limited | Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
US20070053843A1 (en) * | 2003-10-28 | 2007-03-08 | Dawson Michelle L | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE887518A (en) | 1980-02-15 | 1981-08-13 | Glaxo Group Ltd | ANDROSTAN CARTOTHIOATES |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
-
2010
- 2010-01-29 TR TR2010/00685A patent/TR201000685A2/en unknown
-
2011
- 2011-01-28 WO PCT/TR2011/000020 patent/WO2011093818A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028535A2 (en) * | 1999-10-21 | 2001-04-26 | Glaxo Group Limited | Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate |
WO2002069979A2 (en) * | 2001-03-07 | 2002-09-12 | Glaxo Group Limited | Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
WO2003033000A1 (en) * | 2001-10-12 | 2003-04-24 | Glaxo Group Limited | Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
US20070053843A1 (en) * | 2003-10-28 | 2007-03-08 | Dawson Michelle L | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
Also Published As
Publication number | Publication date |
---|---|
TR201000685A2 (en) | 2011-08-22 |
WO2011093818A2 (en) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100018I1 (en) | Preparations and methods for the administration of active substances by the respiratory tract | |
WO2012016889A3 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
IL223783B (en) | Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament | |
TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
JP2010132695A5 (en) | ||
IL216741A (en) | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases | |
IL223795A (en) | Tetrahydro-pyrido-pyrimidine derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments | |
WO2012021715A3 (en) | Stable formulations of linaclotide | |
TR201000680A2 (en) | Pharmaceutical compositions containing tiotropium, formoterol and budesonide | |
WO2013183062A3 (en) | Palatable formulations of ibuprofen | |
WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
TR201000681A2 (en) | Dry powder formulations inhaled. | |
WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
TR201000733A2 (en) | Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate. | |
WO2011093815A3 (en) | Pharmaceutical compositions comprising formoterol and mometasone | |
WO2011152804A3 (en) | Process for dry powder formulations | |
IL213671A (en) | Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments | |
IL210386A (en) | Indole derivatives, pharmaceutical compositions comprising same and use thereof for preparing medicaments for the treatment or prevention of neurodegenerative diseases | |
WO2011101734A3 (en) | Taste-masked powder for suspension compositions of methylprednisolone | |
IL210975A (en) | Enfumafungin derivatives, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for treating fungal infections | |
WO2011093811A3 (en) | Pharmaceutical preparations comprising formoterol and fluticasone | |
IL217519A (en) | Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders | |
WO2012030308A3 (en) | Formulation comprising cellobiose | |
WO2011093812A3 (en) | Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form | |
WO2011093814A3 (en) | A pharmaceutical combination comprising formoterol and ciclesonide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11712062 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11712062 Country of ref document: EP Kind code of ref document: A2 |